Skip to content

Study · In vitro (cells) · 2016

2 results

Clomiphene and Its Isomers Block Ebola Virus Particle Entry and Infection with Similar Potency: Potential Therapeutic Implications.

Nelson EA, Barnes AB, Wiehle RD, Fontenot GK, Hoenen T, White JM

Viruses2 Aug 2016Cited by 38 (Europe PMC)

PMID27490565 (opens in a new tab)PMCIDPMC4997570 (opens in a new tab)DOI10.3390/v8080206 (opens in a new tab)PepBankPUB-27490565
Download PDFPubMedAsk about this study
Jump to 2 results

Summary

The 2014 outbreak of Ebola virus (EBOV) in Western Africa highlighted the need for anti-EBOV therapeutics. Clomiphene is a U.S. Food and Drug Administration (FDA)-approved drug that blocks EBOV entry and infection in cells and significantly protects EBOV-challenged mice. As provided, clomiphene is, approximately, a 60:40 mixture of two stereoisomers, enclomiphene and zuclomiphene. The pharmacokinetic properties of the two isomers vary, but both accumulate in the eye and male reproductive tract, tissues in which EBOV can persist. Here we compared the ability of clomiphene and its isomers to inhibit EBOV using viral-like particle (VLP) entry and transcription/replication-competent VLP (trVLP) assays. Clomiphene and its isomers inhibited the entry and infection of VLPs and trVLPs with similar potencies. This was demonstrated with VLPs bearing the glycoproteins from three filoviruses (EBOV Mayinga, EBOV Makona, and Marburg virus) and in two cell lines (293T/17 and Vero E6). Visual problems have been noted in EBOV survivors, and viral RNA has been isolated from semen up to nine months post-infection. Since the clomiphene isomers accumulate in these affected tissues, clomiphene or one of its isomers warrants consideration as an anti-EBOV agent, for example, to potentially help ameliorate symptoms in EBOV survivors.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study2

2 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Activity measurement

    In cell assays, enclomiphene inhibited filovirus VLP entry with potency similar to clomiphene and zuclomiphene.

    In plain wordsIn cells, enclomiphene blocked filovirus particle entry with potency similar to clomiphene and zuclomiphene.

    Peptide
    Enclomiphene
    Outcome
    DecreaseVLP entry
    Study

    n: not reported in source

    293T/17 and Vero E6 cells
    Comparator
    Clomiphene and zuclomiphene
    Outcome group
    Antiviral activity · Infection
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Clomiphene and its isomers inhibited the entry and infection of VLPs and trVLPs with similar potencies.
    2 context sentences
    Summary · context
    Here we compared the ability of clomiphene and its isomers to inhibit EBOV using viral-like particle (VLP) entry and transcription/replication-competent VLP (trVLP) assays.
    Summary · context
    This was demonstrated with VLPs bearing the glycoproteins from three filoviruses (EBOV Mayinga, EBOV Makona, and Marburg virus) and in two cell lines (293T/17 and Vero E6).
  2. 02LabIn vitro (cells)Activity measurement

    In cell assays, enclomiphene inhibited filovirus trVLP infection with potency similar to clomiphene and zuclomiphene.

    In plain wordsIn cells, enclomiphene blocked filovirus particle infection with potency similar to clomiphene and zuclomiphene.

    Peptide
    Enclomiphene
    Outcome
    DecreasetrVLP infection
    Study

    n: not reported in source

    293T/17 and Vero E6 cells
    Comparator
    Clomiphene and zuclomiphene
    Outcome group
    Antiviral activity · Infection
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Clomiphene and its isomers inhibited the entry and infection of VLPs and trVLPs with similar potencies.
    2 context sentences
    Summary · context
    Here we compared the ability of clomiphene and its isomers to inhibit EBOV using viral-like particle (VLP) entry and transcription/replication-competent VLP (trVLP) assays.
    Summary · context
    This was demonstrated with VLPs bearing the glycoproteins from three filoviruses (EBOV Mayinga, EBOV Makona, and Marburg virus) and in two cell lines (293T/17 and Vero E6).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 12:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.